Study of Etrasimod Oral Treatment in Patients 65 and Older With Active Ulcerative Colitis

What this Trial Is About

This research aims to evaluate the effectiveness and safety of Etrasimod, a novel oral drug, in elderly patients aged 65 years or older who have active ulcerative colitis. The study is focused on treatment and involves elderly patients with this condition to better understand the drugs impact on their disease course and symptoms. Participants will receive 2 mg of Etrasimod daily by mouth. The study is a single-group interventional trial where all participants receive the same treatment. The main treatment period includes assessment of clinical remission after 4 weeks, with additional evaluation of endoscopic improvements and monitoring for adverse events continuing up to 52 weeks. During the study, researchers will collect and analyze clinical data, adverse events, endoscopic findings, and tissue biopsy results from participants. The primary outcome is the rate of clinical remission at 4 weeks measured by a clinical activity index. Secondary outcomes include endoscopic improvements and safety monitoring over one year. Participants will be monitored throughout the study to assess both efficacy and safety of the medication.

Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis